HOUSTON, Oct. 8, 2019 /PRNewswire/ -- Soliton, Inc.,
(Nasdaq: SOLY) ("Soliton" or the "Company"), a medical device
company with a novel and proprietary platform technology licensed
from The University of Texas on behalf
of the MD Anderson Cancer Center ("MD Anderson"), today announced
that the Company's preliminary proof of concept study results using
its Rapid Acoustic Pulse (RAP) device for the treatment of fibrotic
(keloid and hypertrophic) scars has been selected for presentation
via abstract at the American Society for Dermatologic Surgery
("ASDS") Annual Meeting on October 24,
2019. The ASDS Annual Meeting is taking place on
October 24-27, 2019 in Chicago, IL.
------------------------
Join our more than 200K fans here to
follow the Company: https://soly-investors.com
------------------------
"We are pleased to be presenting the results from our initial
follow-up visit to attendees at this important dermatology
conference," stated Christopher
Capelli, MD, founder, President and CEO of Soliton. "We look
forward to being able to share these results with our shareholders
and all interested parties as quickly as possible after the
conference. We view this proof-of-concept trial as the starting
point for demonstrating that our technology could impact other
fibrotic disorders. The same mechanism of action at work to reduce
keloid and hypertrophic scars could likely extend to such
indications as capsular contraction, Peyrone's Disease, and even
liver fibrosis."
Fibrotic scars, such as keloid and hypertrophic scars, represent
wound healing gone awry. Existing published research suggests that
factors relating to the wound-healing environment (including
tension at the boundary of the scar) can cause fibroblasts to
become stuck in a hyper-productive loop, unable to stop the
production of collagen that leads to the thickened, raised and
dense structures often associated with these fibrotic scars.
The American Osteopathic College of Dermatology estimates that
keloids affect around 10 percent of people, whereas hypertrophic
scars are more common. Keloid scars are more prevalent among
populations with darker pigmentation. Hypertrophic scars affect men
and women from any racial group equally, although people between
the ages of 10 and 30 years old are more likely to be affected.
Grand View Research estimates the global market for keloid and
hypertrophic scars may reach $10.2
billion by 2025. There are few treatment options available
for fibrotic scars, which in addition to being disfiguring, can
also cause significant discomfort. Currently, the most common
treatment is the direct injection of steroids into the scar,
however this can require multiple injections and may not be a
permanent solution.
About Soliton, Inc.
Soliton, Inc. is a medical device company with a novel and
proprietary platform technology licensed from MD Anderson. The
Company's first FDA cleared commercial product will use rapid
pulses of acoustic shockwaves as an accessory to lasers for the
removal of unwanted tattoos. The Company is based in Houston, Texas, and is actively engaged in
bringing the Rapid Acoustic Pulse ("RAP") device to the market. The
Company believes this "Soliton" method has the potential to lower
tattoo removal costs for patients, while increasing profitability
to practitioners, compared to current laser removal methods.
Soliton is investigating potential additional capabilities of the
RAP technology in preclinical testing, including the potential to
assist existing fat reduction technology in the reduction of fat as
well as improving the appearance of cellulite by creating
mechanical stress at the cellular level and inducing significant
collagen growth.
For more information about the Company, please
visit: http://www.soliton.com
Forward-Looking Statements
Some of the statements in this release are forward-looking
statements within the meaning of Section 27A of the Securities Act
of 1933, Section 21E of the Securities Exchange Act of 1934 and the
Private Securities Litigation Reform Act of 1995, which involve
risks and uncertainties. Forward-looking statements in this press
release include, without limitation, the ability of the Soliton RAP
device to demonstrate safety and efficacy in the reduction of
keloid and hypertrophic scars, the ability for Soliton to receive
FDA clearance for these additional indications and the ability of
Soliton to pursue treatment of other fibrotic disorders. These
statements relate to future events, future expectations, plans and
prospects. Although Soliton believes that the expectations
reflected in such forward-looking statements are reasonable as of
the date made, expectations may prove to have been materially
different from the results expressed or implied by such
forward-looking statements. Soliton has attempted to identify
forward-looking statements by terminology including ''believes,''
''estimates,'' ''anticipates,'' ''expects,'' ''plans,''
''projects,'' ''intends,'' ''potential,'' ''may,'' ''could,''
''might,'' ''will,'' ''should,'' ''approximately'' or other words
that convey uncertainty of future events or outcomes to identify
these forward-looking statements. These statements are only
predictions and involve known and unknown risks, uncertainties, and
other factors, including those discussed under in our SEC filings,
including under the heading "Item 1A. Risk Factors" in the Form
10-K for year ended December 31, 2018
we filed with the SEC and updated from time to time in our Form
10-Q filings and in our other public filings with the SEC. Any
forward-looking statements contained in this release speak only as
of its date. Soliton undertakes no obligation to update any
forward-looking statements contained in this release to reflect
events or circumstances occurring after its date or to reflect the
occurrence of unanticipated events.
View original
content:http://www.prnewswire.com/news-releases/soliton-to-announce-keloid-and-hypertrophic-scar-clinical-trial-data-on-october-24-2019-300933538.html
SOURCE Soliton, Inc.